Skip to content
Business

Almirall Reports Profit Growth Driven by Dermatology Business

The pharmaceutical company saw a 36% increase in net profit through September 2026, despite missing overall revenue expectations.

By 3 min read

The Spanish pharmaceutical company Almirall announced a significant increase in its financial performance for the first nine months of 2026. According to the company's report, net profit reached 53.3 million euros, marking a 36.3% increase compared to the same period in the previous year. This growth was largely attributed to the strong performance of its dermatology division, which continues to be the primary engine for the firm's revenue.

Total revenue for the period rose to 893.6 million euros, an 8.2% increase over the first nine months of 2025. While the company saw growth in its core dermatology sector, which grew by 17.6% to 568.6 million euros, other areas of the business faced challenges. Specifically, the general medicine division experienced a 4.7% decline in revenue, totaling 320.6 million euros. This divergence in performance has drawn attention from market analysts regarding the company's overall sales momentum.

Operating results showed positive trends, with EBITDA rising 22.7% to 221.7 million euros, achieving a margin of 24.9%. Financial analysts at Jefferies noted that this better-than-expected operating result was supported by higher gross margins and effective control over operating costs. Despite these gains, the company's stock faced downward pressure, falling 8.3% following the release of the results, as total sales figures fell slightly below market consensus expectations.

The company's dermatology portfolio remains the key driver of its strategy. Sales of the psoriasis treatment Ilumetri grew by 11.5%, while the atopic dermatitis treatment Ebglyss saw a substantial 75% increase in revenue. Despite this growth, some analysts expressed concerns that the performance of these key products did not fully meet the higher expectations set by the market, contributing to the negative reaction in share price.

Looking ahead, Almirall has confirmed its annual guidance for 2026, projecting net revenue growth between 9% and 12%. Management indicated that while they expect the operating result to reach the upper end of their target range, total revenue is likely to land in the middle to lower end of their projections. The company also continues to invest heavily in research and development, with expenditures rising 4.6% to 107.1 million euros, representing 12% of net sales.

The company faces potential future challenges, including a German discount reform that could impact 2027 revenue by an estimated 1% to 2.5%. While the exact financial implications remain uncertain, Almirall maintains a focus on its ability to convert revenue growth into increased operational profitability. As the firm moves forward, investors are closely monitoring whether the strength of the dermatology business can continue to offset broader market pressures and internal divisions that are currently underperforming.

Sources

Related stories